Compass Therapeutics, Inc. 8-K

What Happened

• Compass Therapeutics, Inc. filed an 8-K on June 11, 2026 reporting the voting results from its Annual Meeting of Stockholders held June 10, 2026. Stockholders elected two Class III directors, ratified CohnReznick, LLP as the independent auditor for 2026, and approved non-binding advisory votes on executive compensation and the frequency of those votes.

Key Details

• Director elections (Class III, terms through the 2029 Annual Meeting):
  • Thomas J. Schuetz, M.D., Ph.D.: For 102,984,184; Withheld 18,837,499; Broker non-votes 21,320,318.
  • Richard S. Lindahl, M.B.A.: For 103,453,540; Withheld 18,368,143; Broker non-votes 21,320,318.
• Auditor ratification:
  • CohnReznick, LLP ratified as independent registered public accounting firm for year ending Dec 31, 2026: For 137,896,097; Against 181,037; Withheld 5,064,867 (no broker non-votes).
• Executive compensation advisory votes:
  • Advisory approval of named executive officers’ compensation: For 117,963,684; Against 1,796,022; Abstain 2,061,977; Broker non-votes 21,320,318.
  • Advisory vote on frequency: Every Year 118,289,260; Every Two Years 811,275; Every Three Years 1,491,631; Abstain 1,229,517. The board has decided to hold the advisory vote on executive compensation annually.

Why It Matters

• These governance results confirm the board lineup and auditor for 2026, which are material for oversight and financial reporting continuity.
• The strong advisory support for executive compensation and the board’s decision to hold annual advisory votes inform investors about shareholder sentiment on pay and the company’s governance practices.
• All items reported were routine corporate governance matters disclosed in the company’s proxy (Definitive Proxy Statement filed April 29, 2026).